<DOC>
	<DOC>NCT02445352</DOC>
	<brief_summary>The purpose of this study is to evaluate efficacy and safety of DP-R207 in patients with primary hypercholesterolemia.</brief_summary>
	<brief_title>Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Aged over 19 years Signed informed consent form At visit 1 and visit 2, LDLCholesterol ≤ 250mg/dL and Triglyderide ≤ 350mg/dL Has a history of hypersensitivity to HMGCoA reductase inhibitor and component of ezeimibe Liver transaminases &gt; 2 x upper limit of normal</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>